Nachrichten zur Amgen Inc. Aktie

FDA Rejects Amgens (AMGN) NDA Seeking Full Nod for Lumakras

Per the FDA, Amgen (AMGN) will need to complete an additional confirmatory study on Lumakras in certain lung cancer patients…

Amgen’s NDA for Lumakras cancer treatment resulted in complete response letter

…

Amgen: Kurszielerhöhung

Tokio (www.aktiencheck.de) - Rating-Update: Narumi Nakagiri, Analyst von Daiwa Capital Markets, stuft die Aktie von Amgen Inc. (ISIN: US0311621009, WKN: 867900,…

Global Biologics Drug Discovery Market Analysis, 2023-2033: Dominated by AbbVie, Amgen, AstraZeneca, and Pfizer

Dublin, Dec. 19, 2023 (GLOBE NEWSWIRE) -- The "Biologics Drug Discovery Market - A Global and Regional Analysis,…

Amgen shares rise as analysts see ‘value obesity play’

…

Amgen: Hochstufung und neues Kursziel - Aktienanalyse

Toronto (www.aktiencheck.de) - Amgen-Aktienanalyse von BMO Capital Markets: Evan Seigerman, Analyst von BMO Capital Markets, stuft in einer aktuellen Aktienanalyse die…

Amgen lifted at BMO Capital as analysts see 22% potential upside By Investing.com

Amgen lifted at BMO Capital as analysts see 22% potential upside…

Stocks making the biggest moves premarket: Amgen, Sunnova, Arvinas and more

These are the stocks posting the largest moves in premarket trading.…

wikifolio whispers a.m. Intel, McDonalds, Amgen und Deutsche Boerse

Intel 0.31% Silberpfeil60 (BLKCHN): Intel sagt, dass Dutzende von PC-Herstellern seinen neuen KI-fähigen Chip verwenden Intel https://de.tradingview.com/symbols/NASDAQ-INTC/ sagte am Donnerstag,…

AbbVie, Amgen among firms targeted for latest Medicare inflation penalties

…

Breast Cancer Drugs Global Market Report 2024, Featuring Profiles of Key Players Novartis, AstraZeneca, Eli Lilly, Biocon, Merck and MacroGenics

Dublin, Dec. 14, 2023 (GLOBE NEWSWIRE) -- The "Breast Cancer Drugs Global Market Report 2024" has been added…

Amgen: Kursziel gesenkt

New York (www.aktiencheck.de) - Rating-Update: Die Analysten von Morgan Stanley stufen die Aktie von Amgen Inc. (ISIN: US0311621009, WKN: 867900, Ticker-Symbol:…

Amgens (AMGN) Tarlatamab BLA Gets FDA Priority Tag for SCLC

Amgens (AMGN) BLA for tarlatamab to treat advanced small cell lung cancer gets FDAs priority review. A decision is expected…

1 Biotech Stock That Could Be the Next Amgen

The emergence of genomic medicine as a viable modality could transform this midcap biotech into the next Amgen.…

Top 5 NASDAQ Biotech Stocks of 2023

This year the NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) has slowly tracked downward in response to the high volatility seen across global…

: Amgen raises dividend to $2.25 a share

Amgen Inc. AMGN said late Tuesday its board has authorized a dividend of $2.25 a share, up from $2.13 a…

Amgen raises dividend to $2.25 a share

…

Amgen upgraded at RBC on catalyst setup and growth drivers

…

IBM, Nike, Amgen and Salesforce are catalysts as Dow industrials pivot to gain

IBM, Nike, Amgen and Salesforce are catalysts as Dow industrials pivot to gain…

Amgen: Neue Wachstumschancen - Aktienanalyse

Toronto (www.aktiencheck.de) - Amgen-Aktienanalyse von RBC Capital Markets: Gregory Renza, Analyst vom Investmenthaus RBC Capital Markets, stuft die Aktie von Amgen…

RBC Capital upgrades Amgen on improving position of stability and diminishing uncertainty By Investing.com

RBC Capital upgrades Amgen on improving position of stability and diminishing uncertainty…

ARWR: Updates on Plozasiran and Zodasiran at AHA 2023…

By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Updated Clinical Data for Cardiometabolic Candidates Presented at AHA 2023 On November…

KRAS Inhibitors Market Current Trends and Future Scope Analysis Report

Companies covered in this report are Amgen, Boehringer Ingelheim, BridgeBio Pharma, Erasca, Innovent Biologics Inc., Incyte, Mirati Therapeutics, Novartis, Jemincare,…

Multiple Myeloma Market revenue to surpass USD 71 Billion by 2035, says Research Nester

Major multiple myeloma market players include Amgen Inc., Johnson & Johnson, Takeda Pharmaceuticals Company Limited, Novartis AG, Sanofi, Teva Pharmaceuticals…

Global Melanoma Therapeutics Market Size To Worth USD 12.35 Billion By 2032 | CAGR of 9.4%

The Global Melanoma Therapeutics Market Size was valued at USD 5.03 Billion in 2022 and the Worldwide Melanoma Therapeutics Market…

Pro Research: Wall Street takes on Amgens diverse prospects By Investing.com

Pro Research: Wall Street takes on Amgens diverse prospects…

Amazon (AMZN) Teams Up With Amgen, Expands Customer Base

Amazons (AMZN) AWS gets selected by Amgen. This highlights the efficiency and reliability of AWS innovative cloud products and services.…

Amgen Inc. (AMGN) Presents at 6th Annual Evercore ISI HealthCONx Conference (Transcript)

…

Pancreatic Cancer Market revenue to reach USD 36 Billion by 2036, says Research Nester

Key pancreatic cancer market players include Amgen Inc., Novartis AG, Pfizer Inc., Aduro Biotech Inc., Clovis Oncology Inc., NewLink Genetics…

Non-Oncology Biologics and Biosimilars Market is Booming and Expected to Grow at a CAGR of 21.8% to 2031

Companies covered in this report are AbbVie Inc., Sanofi, Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La…

Top Stock Reports for McDonalds, Amgen & NextEra Energy

Todays Research Daily features new research reports on 16 major stocks, including McDonalds Corporation (MCD), Amgen Inc. (AMGN) and NextEra…

Amazon Web Services, Amgen to work on generative AI solutions to advance therapies

…

Pro Research: Wall Street dives into Amgens strategic shifts By Investing.com

Pro Research: Wall Street dives into Amgens strategic shifts…

Biotech Hot Stock erobert 1,8 Mrd. $ Markt - Unmittelbar vor Lizenzdeal. 487% Biotech-Aktie nach 31.205% Amgen ($AMGN)

Calgary (www.aktiencheck.de, Anzeige) Einschätzung Strong OutperformerKurszieleKursziel 12M: 9 USD Kurschance: 291% Kursziel 24M: 13,50 USD Kurschance: 487%StammdatenISIN: CA98420Q3061 WKN: A3EUNZ Ticker: ANUA TSXV: XRTX.V NASDAQ: XRTXKursdatenKurs: 2,30 USD 52W Hoch:…

Amgen: Buy In Stable Fundamental And Technical Price Growth

…

Amgen Is Still A Hold, But Should Be On Your Watchlist

…

Amgen - die volatile Biotech Aktie aus dem Dow Jones

Anzeige / WerbungAmgen - die volatile Biotech Aktie aus dem Dow JonesAmgen ist eine für Trader beliebte Aktie aus dem…

Amgen mit Problemen

Während der letzten Monate gehörte die Aktie von Amgen, einer der führenden US-Biotechnologiekonzerne, zu den großen Gewinnern an der Wall…

Aktienzusammenlegung 9:1 sichert NASDAQ-Listing. Diesen Biotech Aktientip jetzt kaufen nach 31.205% mit Amgen ($AMGN)

Calgary (www.aktiencheck.de, Anzeige) Einschätzung Strong OutperformerKurszieleKursziel 12M: 1,00 EUR Kurschance: 199% Kursziel 24M: 1,50 EUR Kurschance: 348%StammdatenISIN: CA98420Q2071 WKN: A3C9TS Ticker: ANU TSXV: XRTX.V NASDAQ: XRTXKursdatenKurs: 0,335 EUR 52W Hoch:…

Amgen: Portfolio unter Druck erwartet - Coverage aufegnommen - Aktienanalyse

Frankfurt (www.aktiencheck.de) - Amgen-Aktienanalyse von Analyst James Shin von der Deutschen Bank: James Shin, Analyst der Deutschen Bank, stuft die Aktie…

Eilt: Unmittelbar vor Lizenzdeal - Massives Kaufsignal. Diesen Pharma Aktientip kaufen nach 31.205% mit Amgen ($AMGN)

Calgary (www.aktiencheck.de, Anzeige) Einschätzung Strong OutperformerKurszieleKursziel 12M: 1,00 EUR Kurschance: 189% Kursziel 24M: 1,50 EUR Kurschance: 333%StammdatenISIN: CA98420Q2071 WKN: A3C9TS Ticker: ANU TSXV: XRTX.V NASDAQ: XRTXKursdatenKurs: 0,346 EUR 52W Hoch:…

Amgen: Umsetzung der Pipeline - Upgrade! Aktienanalyse

Charlotte, NC (www.aktiencheck.de) - Amgen-Aktienanalyse von Truist: Die Analysten von Truist stufen die Aktie von Amgen Inc. (ISIN: US0311621009, WKN: 867900,…

Eilt: Globaler Lizenzdeal voraus - Neuer 407% Biotech Aktientip nach 31.205% mit Amgen und 134.452% mit Biogen ($BIIB)

Calgary (www.aktiencheck.de, Anzeige) Einschätzung Strong OutperformerKurszieleKursziel 12M: 1,00 EUR Kurschance: 238% Kursziel 24M: 1,50 EUR Kurschance: 407%StammdatenISIN: CA98420Q2071 WKN: A3C9TS Ticker: ANU TSXV: XRTX.V NASDAQ: XRTXKursdatenKurs: 0,296 EUR 52W Hoch:…

Sensationelle Übernahme für 2,2 Mrd. $ - Neuer 392% Biotech Hot Stock nach 31.205% mit Amgen und 134.452% mit Biogen

Calgary (www.aktiencheck.de, Anzeige) Einschätzung Strong OutperformerKurszieleKursziel 12M: 1,00 EUR Kurschance: 228% Kursziel 24M: 1,50 EUR Kurschance: 392%StammdatenISIN: CA98420Q2071 WKN: A3C9TS Ticker: ANU TSXV: XRTX.V NASDAQ: XRTXKursdatenKurs: 0,305 EUR 52W Hoch:…

dpa-AFX ProFeed